FTC and states seek contempt order against Martin Shkreli for breaching pharma work ban

The U.S. Federal Trade Commission, joined by seven states, asked a federal court to hold former biotech executive Martin Shkreli in contempt. The request cites repeated violations of a court order that bars Shkreli from any work in the pharmaceutical industry.

The agency argues that Shkreli’s actions constitute a flagrant disregard for the injunction, and it seeks sanctions to enforce compliance. The contempt filing underscores ongoing regulatory scrutiny of individuals who have previously been barred from the sector.

In related industry news, Sanofi has settled an antitrust investigation by European regulators, though details of the settlement were not disclosed. Additionally, CVS agreed to pay $315 million to resolve a Justice Department case concerning its opioid prescribing practices.

These developments highlight continued enforcement actions across the pharmaceutical landscape, affecting both companies and high‑profile individuals.